LDS/Medical Tests/HBB (Hemoglobin, Subunit Beta) Gene Mutation Analysis

HBB (Hemoglobin, Subunit Beta) Gene Mutation Analysis

The HBB gene is located in the short (p) arm of chromosome 11 at position 15.4. It encodes beta globin protein, which is a component (subunit) of hemoglobin. Hemoglobin within red blood cells binds to oxygen molecules in the lungs. These cells then travel through the bloodstream and deliver oxygen to tissues throughout the body. Mutations in the gene produce several variants of the protein, which are implicated with such disorders such as sickle cell disease, beta thalassemia and methemoglobinemia. A point mutation at position 20, changing AT in the HBB gene, results in glutamine replacing valine at position 6 (Glu6Val) in the beta-chain protein producing hemoglobin S (HbS). When deoxygenated the HbS molecules stick together and form long, rigid chains that bend red blood cells into a sickle (crescent) shape. These sickle-shaped cells are stiff and lack the deformability needed to traverse capillary beds resulting in vessel occlusion, severe pain and organ damage. Althopuygh sickled cells may return to normal shape upon re-oxygenation eventually the cell membranees are sufficiently damaged and the cells become irreversibly sickled and are destroyed resulting in anemia.

Sickle Cell Disease (SCD)

SCD is caused by homozygosity for the HbS mutation. SCD is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage to bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood (termed splenic sequestration) resulting in thrombocytopenia, leukopenia and marked anemia. The spleen is particularly vulnerable to infarction in patients with SCD and the majority of individuals become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, as well as delayed growth and sexual maturation. Individuals with the highest rates of hemolysis are predisposed to pulmonary artery hypertension, priapism, and leg ulcers but may be relatively protected from vaso-occlusive pain.

Individuals who are heterozygous for the HbS mutation have ‘Sickle Cell Trait’. This disorder is relatively clinically benign with only mild anemia and little to no organ damage. It is believed that the HbS mutation has been conserved in the population as it confers some resistance to malaria. Compound heterozygosity for HbS and other HBB mutations cause other disorders similar to SCD such as Hemoglobin SC, SE and SD disease.

Beta-thalassemia (β-thalassemia)

β-thalassemia is characterized by mutations in HBB which prevent (β0) or reduce (β+) the synthesis of beta hemoglobin chains and results in microcytic hypochromic anemia and reduced amounts of hemoglobin A (HbA). Individuals with beta-thalassemia major have little or no beta globin protein production and have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Therapy consists of chronic transfusion, drugs (e.g. luspatercept) and or marrow transplant. Transfused individuals are at risk to develop iron overload and may require chelation therapy. Individuals with β-thalassemia intermedia have some beta chain production, present later in life and have milder anemia that does not require regular blood transfusion.

Methemoglobinemia

In the beta-globin type of methemoglobinemia, mutations in the HBB gene promote the oxidation of heme iron from the ferrous (Fe2+) to ferric (Fe3+) state. This altered hemoglobin cannot bind oxygen, gives the blood a brown color and causes a bluish appearance of the skin, lips, and nails (cyanosis). Clinically, patients with methemoglobinemia have benign cyanosis, although in severe cases, it can cause headaches, weakness, and fatigue.

  • Diagnosis of sickle cell disease, beta thalassemia and methemoglobinemia
  • Useful for diagnosis in at-risk individuals under age 12 months who have a positive or suggestive newborn screening result
  • Carrier and prenatal screening for at risk family members
  • In the evaluation of individuals who have unexplained microcytic hypochromic anemia and/or anisopoikilocytosis and nucleated red blood cells on peripheral blood smear.
For a diagnosis of sickle cell anemia or β-thalassemia to be confidently rendered, a gene mutation must be detected within the HBB gene. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutation or pathogenic variant in HBB gene

Sequence analysis by next generation sequencing or bi-directional sequencing. HBB gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

Whole blood (EDTA), amniotic fluid (prenatal test).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 5-7 days
  • Frozen: Unacceptable
CBC, Hemoglobin, Quantitative HbA2 determination, RBC indices, reverse‐dot‐blotting technique, electrophoresis, sickle solubility testing, hemoglobin electrophoresis, high-performance liquid chromatography (HPLC), and isoelectric focusing (IEF).
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login